Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Collyar: What's In It for Patients?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Nov

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Collyar: What's In It for Patients?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

HER2-Positive Targeted Therapy Cardiovascular Risk: ACC Upcoming Journal Club

Upcoming ASCO AI in Oncology Webinar Turns Chatbot Printouts Into Better Patient Conversations

Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control

Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer

A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery